Last reviewed · How we verify
Omega-3 Ethyl Esters
At a glance
| Generic name | Omega-3 Ethyl Esters |
|---|---|
| Also known as | n-3 fatty acid, Omacor |
| Sponsor | University of Oxford |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction (PHASE2)
- The Effect of Omega 3 Supplementation on Postoperative Delirium in Elderly Patients Undergoing Major Cardiac Surgery (PHASE2)
- Phase II Trial to Modulate Intermediate Endpoint Biomarkers in Former and Current Smokers (PHASE2)
- Testing an Omega-3 Fatty Acid-Based Anti-Cancer Therapy for Patients With Triple-Negative Inflammatory Breast Cancer That Has Spread to Other Parts of the Body (PHASE1, PHASE2)
- The Effect of E-EPA on Circulating LDL and Plasma Lipid Metabolism (NA)
- An Open-label Extension to Assess the Continued Efficacy of Omacor Plus Simvastatin (PHASE4)
- ASCEND: A Study of Cardiovascular Events iN Diabetes (PHASE4)
- EPA for Metastasis Trial 2 (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Omega-3 Ethyl Esters CI brief — competitive landscape report
- Omega-3 Ethyl Esters updates RSS · CI watch RSS
- University of Oxford portfolio CI